Valofane
In today's world, Valofane has become a topic of increasing interest and debate. From its origins to its impact on today's society, Valofane has captured the attention of experts and the general public. As its relevance continues to increase, it is crucial to understand its implications and consequences in different areas. In order to address this question comprehensively, this article seeks to explore the different aspects of Valofane, from its historical origins to its influence today. Through a detailed analysis, it is intended to shed light on this topic in an objective and complete manner, offering the reader a broad and precise vision.
 | |
| Clinical data | |
|---|---|
| Other names | N-carbamoyl-5-methyl-2-oxo-3-prop-2-enyloxolane-3-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.019.871 |
| Chemical and physical data | |
| Formula | C10H14N2O4 |
| Molar mass | 226.232 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Valofane is a sedative drug structurally related to the barbiturates and similar drugs such as primidone. It is metabolized once inside the body to form the barbiturate proxibarbital (proxibarbal) and is thus a prodrug.
References
- ^ Traversa U, Puppini P, Jacquot C, Vertua R (1985). "Effect of an atypical barbiturate, the 2-allophanyl-2-allyl-4-valerolactone (valofan), on exploratory behaviour and brain serotonin concentrations in mice". Journal de Pharmacologie. 16 (3): 279–90. PMID 2415778.
- ^ Lambrey B, Compagnon PL, Jacquot C (1981). "Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats". European Journal of Drug Metabolism and Pharmacokinetics. 6 (3): 161–9. doi:10.1007/BF03189485. PMID 6118275. S2CID 10197120.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |